Advertisement

Gynecology

  • Lane J. Mercer

Abstract

The average age of surgical menopause in the United States is 45.5 years, and that of natural menopause is 51.4 years. Therefore, for many women the postmenopausal period is now longer than time of reproductive function. During the postmenopausal years, many problems of the female reproductive tract can affect a woman’s daily functioning, influence her longevity, and alter her feelings of self-esteem. In recent years, awareness of the postmenopausal woman’s needs has increased, and the scope of gynecologic health care has expanded to meet her expectations.

Keywords

Endometrial Carcinoma Estrogen Replacement Therapy Estrogen Deficiency Adnexal Mass Female Reproductive Tract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Droegemueller MD, Herbst AL, Mishell DR, et al. Pre-malignant and malignant diseases of the vulva. In: Comprehensive Gynecology. St Louis, Mo: CV Mosby Co; 1987: 876–900.Google Scholar
  2. 2.
    Lee SC, Roth LM, Ehrlich C, et al. Extramammary Paget’s disease of the vulva: a clinicopathologic study of 13 cases. Cancer 1977; 39: 2540–2549.PubMedCrossRefGoogle Scholar
  3. 3.
    Rigg LA, Hermann IT, Yen SSC. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298: 195.PubMedCrossRefGoogle Scholar
  4. 4.
    Mandelblatt JS, Fahs MC. The cost-effectiveness of cervical cancer screening for low-income elderly women. JAMA 1988; 259: 1409.CrossRefGoogle Scholar
  5. 5.
    Bibbo M, Kluskens L, Aziz F, et al. Accuracy of three sampling techniques for the diagnosis of endometrial cancer and hyperplasias. J Reprod Med 1982; 27: 622.PubMedGoogle Scholar
  6. 6.
    Gal D, Edman CD, Vellios F, et al. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983; 146: 316.PubMedGoogle Scholar
  7. 7.
    Collins J, Donner A, Allen LH, et al. Oestrogen use and survival in endometril cancer. Lancet 1980; 2: 961.PubMedCrossRefGoogle Scholar
  8. 8.
    Barber HRK, Graber EA. The PMPO syndrome (postmenopausal palpable ovary syndrome). Obstet Gynecol 1971; 38: 921.PubMedGoogle Scholar
  9. 9.
    Koss LG, Schreiber K, Oberlander SG, et al: Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gyecol 1984; 64: 1.Google Scholar
  10. 10.
    Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1167.CrossRefGoogle Scholar
  11. 11.
    Ottosson VE, Johansson BG, VonSchultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151: 746.PubMedGoogle Scholar
  12. 12.
    Luciano AA, Turksoy RN, Carleo J, et al. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988; 71: 39.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Lane J. Mercer

There are no affiliations available

Personalised recommendations